{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:53Z","timestamp":1793145293495,"version":"4.5.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Endometrial cancer (EC) treatment has been revolutionized by the integration of immunotherapy, particularly for molecularly defined subsets of patients. The classification of EC into DNA polymerase epsilon-mutated (POLE-mutant), mismatch repair-deficient (dMMR), p53-abnormal, and no specific molecular profile (NSMP) subtypes provides a critical framework for predicting response to immune checkpoint blockade. dMMR and POLE-mutant tumors, with their hypermutated and immunogenic phenotypes, demonstrate exceptional sensitivity to Programmed Death-1(PD-1) inhibitors such as pembrolizumab and dostarlimab in clinical trials. In contrast, overcoming the immunoresistant nature of NSMP and p53-abnormal EC requires innovative combinations, exemplified by the success of pembrolizumab plus the multitargeted tyrosine kinase inhibitor lenvatinib. Recent practice-changing clinical trials have further established combination strategies incorporating PD-1 blockade with chemotherapy as a new first-line standard for advanced disease, marking a paradigm shift in the management of advanced EC. This review synthesizes the mechanistic basis for these approaches, the compelling clinical evidence supporting approved therapies, and the frontier of investigational strategies, including cellular therapies, novel immune checkpoints, and rational combination regimens\u2014aimed at expanding the benefit of immunotherapy to a broader range of patients with EC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1697065","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:42:04Z","timestamp":1767940924000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengyi","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S499435","article-title":"Global trends in incidence and mortality rates of endometrial cancer among individuals aged 55 years and above from 1990 to 2021: an analysis of the global burden of disease","volume":"17","author":"Gao","year":"2025","journal-title":"Int J Womens Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.022","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.02.030","article-title":"Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma","volume":"161","author":"Raffone","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3241","article-title":"Network for biomarker immunoprofiling for cancer immunotherapy: cancer immune monitoring and analysis centers and cancer immunologic data commons (CIMAC-CIDC)","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.3390\/ijms231911684","article-title":"TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives","volume":"23","author":"Arciuolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01131-6","article-title":"Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma","volume":"35","author":"Chen","year":"2022","journal-title":"Mod Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102701","DOI":"10.1016\/j.ctrv.2024.102701","article-title":"Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer","volume":"125","author":"Bartoletti","year":"2024","journal-title":"A meta-analysis. Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.humpath.2024.105704","article-title":"PD-L1 expression and immune infiltration across molecular subtypes of endometrial cancer: An integrative-analysis of molecular classification and immune subtypes","volume":"154","author":"Zhang","year":"2024","journal-title":"Hum Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1308875","article-title":"Corrigendum: 6-Shogaol inhibits oxidative stress-induced rat vascular smooth muscle cell apoptosis by regulating OXR1-p53 axis","volume":"10","author":"Liu","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ijms25021278","article-title":"EphA2- and HDAC-targeted combination therapy in endometrial cancer","volume":"25","author":"Joseph","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2022-0013","article-title":"Pan-cancer Landscape of the RUNX Protein Family Reveals their Potential as Carcinogenic Biomarkers and the Mechanisms Underlying their Action","volume":"10","author":"Pan","year":"2022","journal-title":"J Transl Int Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/cancers15153837","article-title":"Precision medicine: disease subtyping and tailored treatment","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajcr.12063","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J BioMed Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"114712","DOI":"10.1016\/j.biopha.2023.114712","article-title":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic Malignancies","volume":"162","author":"Li","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e180516","DOI":"10.1172\/JCI180516","article-title":"Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer","volume":"134","author":"G\u00f3mez-Banoy","year":"2024","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S257188","article-title":"A review about pembrolizumab in first-line treatment of advanced NSCLC: focus on KEYNOTE studies","volume":"12","author":"Qu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.01.012","article-title":"Pembrolizumab in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) and non-MSI-H\/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results","volume":"193","author":"O\u2019Malley","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.02.026","article-title":"Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy","volume":"599","author":"Park","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.3390\/ijms26157151","article-title":"Feasibility of manufacturing and antitumor activity of TIL for advanced endometrial cancers","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.20517\/cdr.2023.120","article-title":"The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer","volume":"7","author":"Martinez-Cannon","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00084","article-title":"Abscobal effect of balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer","volume":"40","author":"Aslan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2024.09.008","article-title":"Concurrent POLE hotspot mutations and mismatch repair deficiency\/microsatellite instability in endometrial cancer: A challenge in molecular classification","volume":"191","author":"Moufarrij","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30079-8","article-title":"Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer","volume":"20","author":"Konecny","year":"2019","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12916-025-03989-0","article-title":"Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer","volume":"23","author":"Wang","year":"2025","journal-title":"BMC Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/ijms24043915","article-title":"Combination of ephA2- and wee1-targeted therapies in endometrial cancer","volume":"24","author":"Dasari","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/pharmaceutics15092241","article-title":"Targeting DNA damage repair and immune checkpoint proteins for optimizing the treatment of endometrial cancer","volume":"15","author":"Bian","year":"2023","journal-title":"Pharmaceutics"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.041","article-title":"Promising novel therapies for the treatment of endometrial cancer","volume":"116","author":"Gehrig","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic Malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00957-5","article-title":"Tumor-infiltrating lymphocyte therapy for the treatment of metastatic melanoma","author":"Tsai","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"115329","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132\u201301 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/cancers15072042","article-title":"Immune environment and immunotherapy in endometrial carcinoma and cervical tumors","volume":"15","author":"Lain\u00e9","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e011479","DOI":"10.1136\/jitc-2025-011479","article-title":"O-GlcNAc transferase promotes immune evasion and immunotherapy resistance in uterine corpus endometrial cancer by targeting the glucocorticoid receptor","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.012","article-title":"Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis","volume":"124","author":"Brunner","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163136","article-title":"IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer","volume":"14","author":"Lutz","year":"2023","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45040220","article-title":"The current status and future perspectives of chimeric antigen receptor-engineered T cell therapy for the management of patients with endometrial cancer","volume":"45","author":"Choi","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.725330","article-title":"Engineered T cell therapy for gynecologic Malignancies: challenges and opportunities","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/jtim-2025-0005","article-title":"Senescent cells as a target for anti-aging interventions: From senolytics to immune therapies","volume":"13","author":"Fu","year":"2025","journal-title":"J Transl Int Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390876","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: A synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.012","article-title":"Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma","volume":"159","author":"Wallbillich","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3689","article-title":"Targeted and shallow whole-genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers","volume":"30","author":"Jamieson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod Pathol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051073","article-title":"Myeloid-derived suppressor cells as therapeutic targets in uterine cervical and endometrial cancers","volume":"10","author":"Mabuchi","year":"2021","journal-title":"Cells"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0991","article-title":"Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model","volume":"14","author":"Yoshida","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2304443","DOI":"10.1080\/21688370.2024.2304443","article-title":"The interplay between the epithelial permeability barrier, cell migration and mitochondrial metabolism of growth factors and their inhibitors in a human endometrial carcinoma cell line","volume":"12","author":"Konno","year":"2024","journal-title":"Tissue Barriers"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70584","article-title":"Significance of gelsolin superfamily genes in diagnosis, prognosis and immune microenvironment regulation for endometrial cancer","volume":"14","author":"Jiang","year":"2025","journal-title":"Cancer Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0251-7","article-title":"TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers","volume":"32","author":"Moore","year":"2019","journal-title":"Mod Pathol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0146-7","article-title":"Structural basis of ubiquitin modification by the Legionella effector SdeA","volume":"557","author":"Dong","year":"2018","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1515\/jtim-2025-0019","article-title":"Harnessing the potential of small extracellular vesicle biomarkers for cancer diagnosis and prognosis with advanced analytical technologies","volume":"13","author":"Tam","year":"2025","journal-title":"J Transl Int Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41467-018-08165-y","article-title":"Cross-lineage protection by human antibodies binding the influenza B hemagglutinin","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01887","article-title":"Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors","volume":"43","author":"Slomovitz","year":"2025","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.07.008","article-title":"Immunotherapy in MSI\/dMMR tumors in the perioperative setting: The IMHOTEP trial","volume":"54","author":"Coutzac","year":"2022","journal-title":"Dig Liver Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000006080","article-title":"Molecular characterization and clinical implications of endometrial cancer","volume":"146","author":"Secord","year":"2025","journal-title":"Obstet Gynecol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"117321","DOI":"10.1016\/j.bcp.2025.117321","article-title":"Bavachinin exerts anti-tumor effects by activating TLR4\/STING axis-dependent PANoptosis and synergistically enhances chemosensitivity in endometrial cancer","volume":"242","author":"Shu","year":"2025","journal-title":"Biochem Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1697065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:42:05Z","timestamp":1767940925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1697065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2025.1697065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1697065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1697065"}}